News

Zacks Small Cap Research on MSN25m

AEMD: Cohort 2 Enrollment Open; Initial Cohort 1 Data Analysis Expected Next Month

AEMD READ THE FULL AEMD RESEARCH REPORT ENROLLMENT FOR ONCOLOGY TRIAL COHORT 2 HAS COMMENCED Data Safety Monitoring Board Recommended AEMD Progress Trial Without Modification Aethlon Medical ...
The Manila Times1h

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...

Crescent Biopharma: Chasing The Summit Hype

Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody. Read why I rate CBIO stock as a ...